Project Grant R21AI180552
Award Date
7/24/25
Completion Date
6/30/27
Dollars Obligated
$490K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award of $217,337 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to elucidate the role of the SARS-CoV-2 ORF9B protein in virus replication. The research aims to investigate the impact of ORF9B phosphorylation on SARS-CoV-2 replication and generate a detailed interaction map of ORF9B during infection, in order to provide significant insights into the biological...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $899,935 to the Scripps Research Institute to identify novel B cell epitopes on the SARS-CoV-2 spike protein and other human coronaviruses. The goal is to uncover broadly neutralizing antibody epitopes that can inform the design of next-generation COVID-19 vaccines and therapeutics, enhancing pandemic preparedness. The...
This Project Grant award of $582,618.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The grant supports research to determine the mechanisms by which RNA N6-methyladenosine (m6A) and pseudouridine (Ψ) modifications modulate SARS-CoV-2 replication, gene expression, immunity, and pathogenesis. Key activities include using CRISPR-Cas9 to knock out host RNA...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $867,563 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Rockefeller University. The grant supports the development of a pioneering class of nanobodies engineered from llama immune systems to provide comprehensive protection against all betacoronaviruses, including SARS-CoV-1, MERS-CoV, and SARS-CoV-2. Key goals include strategically expanding nanobody repertoires, identifying...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $247,750 to support structural investigations of the SARS-CoV-2 spike protein. The research aims to characterize how glycosylation (the addition of sugar molecules) of the spike protein affects its structure and function, which is critical for virus entry and immune system interactions. This research will...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $437,895 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Research Foundation For The State University Of New York (RF SUNY) to investigate the role of the 90K protein in SARS-CoV-2 infection. The key objectives are to provide mechanistic evidence on the effect of 90K during SARS-CoV-2 infection and to identify how SARS-CoV-2 accessory proteins may counteract 90K's antiviral activity. This...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $489,500.00 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to conduct research on overcoming technical obstacles in understanding the assembly and regulation of B cell antigen receptors (BCRs). The research aims to elucidate the structural details of BCR assembly and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) provides $190,058 to the University of Massachusetts Medical School to investigate the role of the ADAM9 protein in the immune response to SARS-CoV-2 infection. The goal is to define how ADAM9 impacts the immunopathogenesis of severe COVID-19 and its effects on acute lung injury. The research will build on the grantee's preliminary findings...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Vermont & State Agricultural College (UVM) in the amount of $438,983. The award, which runs from July 8, 2025 to June 30, 2027, will fund research to study the biological impact of a stable nucleocapsid (N) protein dimer formation in SARS-CoV-2. Specifically, the research aims to characterize viral growth...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $243,713.00 to the University of Massachusetts Medical School to conduct comprehensive research on the evolution of drug resistance in SARS-CoV-2. The project aims to systematically investigate the interdependence of mutations that disrupt drug binding and those that increase enzyme activity, which are typically...